Letter: Real-World 48-Week Outcomes of Tralokinumab Treatment for Prurigo Nodularis–Like Atopic Dermatitis: A Japanese Retrospective Study

Abstract

Get full access to this article

View all access options for this article.

References

Girolomoni

, de Bruin-Weller

, Aoki

, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021; 12:20406223211002979; doi: 10.1177/20406223211002979

Nomura

, Sandilands

, Akiyama

, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007; 119(2):434–440; doi: 10.1016/j.jaci.2006.12.646

Silverberg

, Adam

, Zirwas

, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: An ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022; 23(4):547–559; doi: 10.1007/s40257-022-00702-2

Hagino

, Onda

, Saeki

, et al. Effects of tralokinumab on clinical and laboratory indexes in atopic dermatitis: A 24-week real-world study. Dermatitis. 2025; 36(3):235–243; doi: 10.1089/derm.2024.0323

Hagino

, Saeki

, Fujimoto

, et al. Effectiveness of tralokinumab for different anatomical sites and clinical signs in atopic dermatitis: A 36-week real-world study. Dermatitis. 2025; doi: 10.1089/derm.2024.0538